Rabeximod

TargetMol
Product Code: TAR-T34249
Supplier: TargetMol
CodeSizePrice
TAR-T34249-1mg1mg£278.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34249-5mg5mg£586.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34249-10mg10mg£804.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34249-25mg25mg£1,171.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34249-50mg50mg£1,556.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34249-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T34249-500mg500mg£4,006.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Rabeximod(ROB-8030) is an immunomodulator that can effectively reduce disease severity in mouse models of autoimmune diseases. Rabeximod inhibits arthritis by stimulating the downstream of TLR2 and TLR4 to block the activation of inflammatory cells (most likely macrophages) in a time-dependent manner. Rabeximod can effectively reduce the brain antigen presentation in mice during the anti-inflammatory treatment of traumatic brain injury.
CAS:
872178-65-9
Formula:
C22H24ClN5O
Molecular Weight:
409.92
Pathway:
Immunology/Inflammation
Purity:
0.98
SMILES:
CN(C)CCNC(=O)Cn1c2ccc(Cl)cc2c2nc3cc(C)c(C)cc3nc12
Target:
TLR

References

Hultqvist M, et al. The novel small molecule drug Rabeximod is effective in reducing disease severity of mouse models of autoimmune disorders. Ann Rheum Dis. 2009 Jan;68(1):130-5. Hultqvist M, et al. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Ann Rheum Dis. 2010;69(8):1527-1532. Giusti P, et al. The novel anti-rheumatic compound Rabeximod impairs differentiation and function of human pro-inflammatory dendritic cells and macrophages. Immunobiology. 2011 Jan-Feb;216(1-2):243-50. Hultqvist M, et al. Rabeximod reduces arthritis severity in mice by decreasing activation of inflammatory cells. Ann Rheum Dis. 2010 Aug;69(8):1527-32.